Edesa Biotech (EDSA) has released an update.
Edesa Biotech reported a significant decrease in operating expenses for fiscal year 2024, with a pivot towards government-funded projects to advance its drug development pipeline. The company strengthened its balance sheet through strategic financial management and received additional funding post-fiscal year, positioning itself well for future opportunities.
For further insights into EDSA stock, check out TipRanks’ Stock Analysis page.